The gut microbiota profile in psoriasis: A Brazilian case‐control study

2021 ◽  
Author(s):  
Lilian Schade ◽  
Dany Mesa ◽  
Adriane Reichert Faria ◽  
Jesus Rodriguez Santamaria ◽  
Camila Alexandre Xavier ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Case Control Study ◽  
Case Control ◽  
Control Study ◽  
Brazilian Case

scholarly journals Gut microbiota composition and arterial stiffness measured by pulse wave velocity: case–control study protocol (MIVAS study)

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e038933
Author(s):  
Rita Salvado ◽  
Sandra Santos-Minguez ◽  
Cristina Agudo-Conde ◽  
Cristina Lugones-Sanchez ◽  
Angela Cabo-Laso ◽  
...  
Keyword(s):  
Arterial Stiffness ◽  
Gut Microbiota ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Intestinal Microbiota ◽  
Pulse Wave ◽  
Case Control Study ◽  
Case Control ◽  
Microbiota Composition ◽  
Control Study

IntroductionIntestinal microbiota is arising as a new element in the physiopathology of cardiovascular diseases. A healthy microbiota includes a balanced representation of bacteria with health promotion functions (symbiotes). The aim of this study is to analyse the relationship between intestinal microbiota composition and arterial stiffness.Methods and analysisAn observational case—control study will be developed. Cases will be defined by the presence of at least one of the following: carotid-femoral pulse wave velocity (cf-PWV), Cardio-Ankle Vascular Index (CAVI), brachial ankle pulse wave velocity (ba or ba-PWV) above the 90th percentile, for age and sex, of the reference population. Controls will be selected from the same population as cases. The study will be developed in Primary Healthcare Centres. We will select 500 subjects (250 cases and 250 controls), between 45 and 74 years of age. Cases will be selected from a database that combines data from EVA study (Spain) and Guimarães/Vizela study (Portugal). Measurements: cf-PWV will be measured using the SphygmoCor system, CAVI, ba-PWV and Ankle-Brachial Index will be determined using VaSera device. Gut microbiome composition in faecal samples will be determined by 16S ribosomal RNA sequencing. Lifestyle will be assessed by food frequency questionnaire, adherence to the Mediterranean diet and IPAQ (International Physical Activity Questionnaire). Body composition will be evaluated by bioimpedance.Ethics and disseminationThe study has been approved by ‘Committee of ethics of research with medicines of the health area of Salamanca’ on 14 December 2018 (cod. 2018-11-136) and the ’Ethics committee for health of Guimaraes’ (Portugal) on 15 October 2019 (ref: 67/2019). All study participants will sign an informed consent form agreeing to participate in the study, in compliance with the Declaration of Helsinki and the WHO standards for observational studies. The results of this study will allow a better description of gut microbiota in patients with arterial stiffness.Trial registration detailsClinicalTrials.gov, identifier NCT03900338

Association of EGFR c.2073A>T polymorphism with decreased risk of diffusely infiltrating astrocytoma in a Brazilian case-control study

2008 ◽  
Vol 23 (3) ◽  
pp. 140-146 ◽  
Author(s):  
K.C. Barbosa ◽  
S.M. Oba-Shinjo ◽  
M. Uno ◽  
P.O. Carvalho ◽  
S. Rosemberg ◽  
...  
Keyword(s):  
Case Control Study ◽  
Case Control ◽  
Control Study ◽  
Brazilian Case

scholarly journals Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study

BMC Medicine ◽  
2013 ◽  
Vol 11 (1) ◽  
Author(s):  
Mora Murri ◽  
Isabel Leiva ◽  
Juan Miguel Gomez-Zumaquero ◽  
Francisco J Tinahones ◽  
Fernando Cardona ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Gut Microbiota ◽  
Case Control Study ◽  
Case Control ◽  
Healthy Children ◽  
Control Study

Gut Microbiota in Burned Patients with Clostridioides difficile Infection: A Case-Control Study

Burns ◽  
2021 ◽  
Author(s):  
Parisa Shoaei ◽  
Hasan Shojaei ◽  
Seyed Davar Siadat ◽  
Arfa Moshiri ◽  
Bahareh Vakili ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Case Control Study ◽  
Case Control ◽  
Clostridioides Difficile ◽  
Clostridioides Difficile Infection ◽  
Control Study

scholarly journals Gut microbiota diversity and T1DM onset: Preliminary data of a case-control study

2017 ◽  
Vol 5-6 ◽  
pp. 11-13 ◽  
Author(s):  
Deborah Traversi ◽  
Ivana Rabbone ◽  
Maria Giovanna Ignaccolo ◽  
Giulia Carletto ◽  
Irene Racca ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Preliminary Data ◽  
Case Control Study ◽  
Case Control ◽  
Microbiota Diversity ◽  
Control Study

scholarly journals No distinction in the gut microbiota between diarrhea predominant-irritable bowel syndrome and healthy subjects: matched case–control study in Thailand

Gut Pathogens ◽  
2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Sawangpong Jandee ◽  
Suppana Chuensakul ◽  
Suppasil Maneerat
Keyword(s):  
Clinical Trial ◽  
Gut Microbiota ◽  
Healthy Subjects ◽  
Case Control Study ◽  
Fecal Microbiota ◽  
Case Control ◽  
Matched Case ◽  
Irritable Bowel ◽  
Matched Case Control Study ◽  
Control Study

Abstract Background Alteration in the gut microbiota has been proposed in irritable bowel syndrome (IBS) pathogenesis, especially in the diarrheal type (IBS-D). We conducted this study to evaluate the fecal microbiota in Thai IBS-D patients when compared with healthy subjects as well as to evaluate the effects of probiotics on changes in the gut microbiota correlated with symptoms. Methods A matched case–control study was conducted on diagnosed IBS-D patients, based on the Rome IV criteria and healthy controls. Stool samples were collected in preservation tubes. Bacterial deoxyribonucleic acid extraction was performed and amplified. Next, 16S ribosomal ribonucleic acid genes sequencing was performed to identify the microbiome in both the groups. IBS-D patients were provided with a probiotic mixture that was rich in Lactobacillus acidophillus and Bifidobacterium bifidum over 8 weeks. Changes in the symptoms, stool characteristics, and fecal microbiota were evaluated and compared with the corresponding baseline values. Results Twenty IBS-D patients with 20 age and gender-matched controls were included in this study. The baseline characteristics were not significantly different between the groups, including the mode of birth and the history of breastfeeding in infancy. No significant difference was noted in the fecal microbiota between the IBS-D patients and controls. The IBS symptom severity scales (IBS-SSS) were not statistically different after probiotic prescription; although, the bowel movements, the sense of urgency to go to the toilet and passing of mucous stool had obviously decreased. No change was noted in the fecal microbiota after receiving the experimental probiotic, except for an increase in the proportion of B. bifidum. Conclusion Alteration in the gut microbiota composition was probably not the main pathogenic mechanism in the Thai IBS-D patients assessed in this study. However, modifying microbiomes with potentially protective bacteria seems to be a beneficial therapy. Thai Clinical trial registry: TCTR20191211006, Date of registration: 10 Dec 2019. Retrospectively registered, Clinical trial URL: www.clinicaltrials.in.th

scholarly journals Characteristics of the Gut Microbiota and Metabolism in Patients With Latent Autoimmune Diabetes in Adults: A Case-Control Study

2021 ◽  
Author(s):  
Yuanyuan Fang ◽  
Chenhong Zhang ◽  
Hongcai Shi ◽  
Wei Wei ◽  
Jing Shang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Gut Microbiota ◽  
Case Control Study ◽  
Autoimmune Diabetes ◽  
Case Control ◽  
Latent Autoimmune Diabetes ◽  
Control Study

OBJECTIVE <p>Type 1 and type 2 diabetes are associated with gut dysbiosis. However, the relationship between the gut microbiota and latent autoimmune diabetes in adults (LADA), sharing clinical and metabolic features with classic type 1 and type 2 diabetes, remains unclear. Here, we identified the characteristics of the gut microbiota and metabolic profiles in patients with LADA using a multi-omics approach.</p> <p>RESEARCH DESIGN AND METHODS</p> <p>This age- and sex-matched case-control study included 30 patients with LADA, 31 patients with classic type 1 diabetes, 30 patients with type 2 diabetes, and 29 healthy individuals. The gut microbiota profiles were identified via the 16S rRNA gene, and fecal and serum metabolites were measured via untargeted liquid chromatography-mass spectrometry.</p> <p>RESULTS </p> <p>LADA patients had a significantly different structure and composition of the gut microbiota and their metabolites as well as a severe deficiency of short-chain fatty acid-producing bacteria. The gut microbiota structure of the LADA patients was more similar to that of patients with type 1 diabetes who were positive for GAD antibody. We identified seven serum metabolite modules and eight fecal metabolite modules that differed between the LADA group and the other groups.</p> <p>CONCLUSIONS </p> <p><a>The characteristic gut microbiota and related metabolites of patients with LADA are associated with autoantibodies, glucose metabolism, islet function, and inflammatory factors, which may contribute to the pathogenesis of LADA. </a>Future longitudinal studies should explore whether modulating the gut microbiota and related metabolites can alter the natural course of autoimmune diabetes, in the quest for new therapeutic.</p>

Sign in / Sign up

Export Citation Format

Share Document